

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

TARPLIN DOWNS & YOUNG LLC

2. Address:

1212 New York Avenue, NW Suite 1050, Washington, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: JENNIFER B. YOUNG

Telephone: 2028984733

E-mail (optional): JYoung@tdylc.com

Senate ID #: 304736-152

House ID #:

7. Client Name: ☐ Self

WYETH

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 100,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: TARPLIN DOWNS & YOUNG LLC Client Name: WYETH

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

FDA Appropriations Critical Path Drug Safety Human Drug Review H. Con. Res. 99/S. Con. Res. 21 - Budget Resolution, Medicare and Medicaid Drug Reimbursement

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DOWNS, RAISSA H

Covered Official Position (if applicable): N/A

Name: FORDJOUR, ISAAC

Covered Official Position (if applicable): N/A

Name: TARPLIN, LINDA E

Covered Official Position (if applicable): N/A

Name: YOUNG, JENNIFER B

Covered Official Position (if applicable): ASSISTANT SECRETARY FOR LEGISLATION, HHS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

***, no specific bill(s), Alzheimers Research, Hormone Replacement Therapy

17. House(s) of Congress and Federal agencies contacted:

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DOWNS, RAISSA H

Covered Official Position (if applicable): N/A

Name: FORDJOUR, ISAAC

Covered Official Position (if applicable): N/A

Name: TARPLIN, LINDA E

Covered Official Position (if applicable): N/A

Name: YOUNG, JENNIFER B

Covered Official Position (if applicable): ASSISTANT SECRETARY FOR LEGISLATION, HHS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

S. 3/H.R. 4 - Medicare Prescription Drug Price Negotiation Act of 2007 Medicare Part D "Non-Interference" Proposals S. 250 - Medicare Enhancements for Needed Drugs Act of 2007 ^{****}, no specific bill(s), Medicare and Medicaid Drug Reimbursement Medicare and Medicaid Drug Reimbursement H.R. 3162 - Children's Health and Medicare Protection Act of 2007 S. 1893 - Children's Health Insurance Program Reauthorization Act of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DOWNS, RAISSA H

Covered Official Position (if applicable): N/A

Name: FORDJOUR, ISAAC

Covered Official Position (if applicable): N/A

Name: TARPLIN, LINDA E

Covered Official Position (if applicable): N/A

Name: YOUNG, JENNIFER B

Covered Official Position (if applicable): ASSISTANT SECRETARY FOR LEGISLATION, HHS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

Drug Safety S. 1082 - Prescription Drug User Fee Amendments of 2007 H.R. 2900 - Food and Drug Administration Amendments of 2007 Follow-on Biologics H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 S. 623/H.R. 1038 - Access to Life-Saving Medicine Act S. 1695 - Biologics Price Competition and Innovation Act of 2007 S. 1505 - Affordable Biologics for Consumers Act ****, no specific bill(s), Follow-On Biologics, Drug Safety, PDUFA Reauthorization **** see addendum page

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DOWNS, RAISSA H

Covered Official Position (if applicable): N/A

Name: FORDJOUR, ISAAC

Covered Official Position (if applicable): N/A

Name: TARPLIN, LINDA E

Covered Official Position (if applicable): N/A

Name: YOUNG, JENNIFER B

Covered Official Position (if applicable): ASSISTANT SECRETARY FOR LEGISLATION, HHS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: JENNIFER B. YOUNG - PARTNER -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: -